The Due Diligence Imperative: Healthcare Reimbursement Environment (Part Two of a Six Part Series)

As discussed in the first installment of this six-part series, *due diligence* may be generally defined as:

(1) "*such a measure of prudence, activity, or assiduity, as is properly to be expected from, and ordinarily exercised by, a reasonable and prudent man under the particular circumstances; not measured by any absolute standard, but depending on the relative facts of the special case*"; and,

(2) "*an investigation in order to support the purchase price of the business*."[1]

There are two distinct classes of information generally required for *due diligence* related to a healthcare valuation engagement:

(1) *General research* – Research that is not specifically related to, or obtained from, the subject *enterprise*, *asset*, or *service* being appraised; and,

(2) *Specific research* – Information specific to the subject *enterprise*, *asset*, or *service*, that is typically obtained from the client or the appropriate contact designated by the client.[2]

The first part of this six-part series set forth an overview of the due diligence imperative for valuation professionals, in the context of the *Four Pillars of Healthcare Value*, i.e., *Reimbursement*, *Regulatory*, *Technology*, and *Competition*.[3] This second installment will review the due diligence process as relates to *healthcare reimbursement*.

Healthcare reimbursement may be defined as the payment received by providers for the services that they render to patients, most of which reimbursement is received from third party payors, e.g., public (government) and private (commercial) payors.[4] The U.S. government is the largest payor of medical costs, primarily through the Medicare and Medicaid programs; this significant market share allows the U.S. government to exert a strong influence on the healthcare reimbursement environment.[5] In 2015, Medicare and Medicaid accounted for an estimated $646.2 billion and $545.1 billion in healthcare spending, respectively, combining for approximately 37 percent of all healthcare expenditures.[6] The prevalence of these public payors in the healthcare marketplace often results in their acting as a *price setter,* i.e., being used as a *benchmark for private reimbursement rates*.[7] The healthcare reimbursement environment is currently undergoing a paradigm shift, from reimbursement based on the *volume* of services provided, to reimbursement based on the *value* of services provided, which shift was recently manifested in the move away from the *sustainable growth rate* (SGR), and the passage of the *Medicare Access and CHIP Reauthorization Act of 2015* (MACRA). This volatility requires the analyst to conduct a thorough and robust due diligence exercise, as the reimbursement trends of the past may not hold true in the future.

In conducting the *general research* related to the subject interest being appraised, the analyst should first develop knowledge base related to the healthcare reimbursement environment, obtain the data required to benchmark the reimbursement at issue in the engagement, and, based on that, reach an adequate understanding of the pertinent reimbursement trends in the marketplace, all of which will allow the analyst to develop their observations, findings, conclusions, and opinion, and determine any necessary assumptions to be made regarding these future trends related to the subject property interest being appraised . One of the principal valuation techniques for which the general research is used is *reimbursement benchmarking*.

In order to compare the reimbursement being received by the subject interest, the analyst may utilize industry normative benchmark survey data, depending on the type of reimbursement involved. For example, reimbursement rates may differ depending on whether: (1) the payor is public or private; (2) the services being provided is in an inpatient or outpatient setting; and/or, (3) the reimbursement at issue relates to the professional or technical component (i.e., whether it is payment for the work of the provider, or for the use of a facility). Upon an assessment of these factors, the analyst can then determine the type of reimbursement benchmark survey data that is most appropriate.

Some of the information that the analyst may want to determine in order to facilitate the benchmarking analysis may include, but not is limited to:

(1) Medicare payments in the base year;
(2) Medicare reimbursement rates on a specific date (of the project);
(3) Projected Medicare reimbursement for the next three to five years;

© HEALTH CAPITAL CONSULTANTS
(Continued on next page)

(4) Medicaid to Medicare fee index; and,
(5) Commercial insurance reimbursement rates.

The various sources of information (some of which sources are free and some of which are available for purchase) that may contain this information may include, but are not limited to:

(1) American Hospital Directory, which "*provides data and statistics about more than 7,000 hospitals nationwide… [and] includes both public and private sources such as Medicare claims data, hospital cost reports, and commercial licensors*";[8]
(2) GuideStar, which aggregates nonprofit reports and Internal Revenue Services (IRS) Form 990s for over 1.8 million non-profit organizations;[9]
(3) Medicare Cost Reports,[10] which contain various data points for a facility, such as "*facility characteristics, utilization data, [and] cost and charges by cost center*";[11]
(4) Physician Compare,[12] published by CMS, which allows the public to compare providers enrolled in Medicare across numerous data points, including utilization and payment data;
(5) Provider compensation and productivity survey data from associations such as:
    (a) *Medical Group Management Association* (MGMA);[13] and,
    (b) *American Medical Group Association* (AMGA);[14]
(6) The relevant Medicare Fee Schedule from CMS;[15]
(7) The state's workers' compensation fee schedule(s);
(8) The state's Medicaid fee schedule(s); and,
(9) Definitive Healthcare, which reports financial and clinical metrics (including net patient revenue, operating income, and average payment per claim by provider) for hospitals and healthcare providers;[16]
(10) FAIR Health, which aggregates information on medical claims (by CPT code) from a significant number of commercial insurers across the U.S.;[17] and,
(11) The Henry J. Kaiser Family Foundation, which provides the Medicaid to Medicare fee index (note that, the data is stratified by state, and by primary care, obstetric care, or other).[18]

The above information presents some of the data sources and means by which the analyst may perform the requisite analysis for comparing the subject reimbursement at issue to industry normative benchmarking data, and provides the context by which the current reimbursement environment can be contrasted with historic trends, to facilitate the analyst's assumptions and calculations necessary to predict future reimbursement.

As noted above, *specific research* is typically collected from the Subject Entity, and specifically from the client, or the appropriate contact designated by the client, e.g., chief information officer (CIO), chief financial officer (CFO), or legal counsel, when pertinent. As the requested documents and information are gathered, an engagement-specific database may be useful to *appropriately* account for the data in a manner that adequately *identifies*, *classifies*, and *stores* it, so that it may be *timely* and *efficiently retrieved* for use (ICSR).

The reimbursement data requested of, and obtained from, the Subject Entity should include both the charges and collections, as well as the amount actually received by the Subject Entity (i.e., the reimbursement). The information and documents to be requested from the Subject Entity may include, but are not limited to:

(1) An aged schedule of accounts receivable with payor detail for the pertinent period;
(2) Productivity reports (which reports should include admissions, payor mix, case mix, and revenue, by payor), such as incidence schedules by the appropriate reimbursement codes, for example:
    (a) *Relative Value Units* (RVU), for use in determining physician reimbursement;
    (b) *Current Procedural Terminology* (CPT) for physician procedures in both inpatient and outpatient settings;
    (c) *Diagnosis Related Groups* (DRG), for use in the hospital setting;
    (d) *Ambulatory Payment Classifications* (APCs), for use in the outpatient setting;
    (e) *Healthcare Common Procedure Coding System* (HCPCS), for classifying ancillary services and procedures;
    (f) *Resource Utilization Groups* (RUGs), for use in the skilled nursing home setting; and,
    (g) Covered lives, for use in relation to managed care companies; and,
(3) A list of any Medicare, Medicaid, and/or other third party payor audits that have been performed or are pending for the Subject Entity, including the audit date and the outcome of the audit.

In the alternative to requesting and obtaining the data piecemeal from the Subject Entity, the analyst may request that the client, or the appropriate contact designated by the client, provide them with a "*data dump*" from the provider's patient billing system, which will include most of the data required to analyze the reimbursement related to the Subject Entity. Most revenue cycle software packages, e.g., Epic Systems and Meditech, allow this data to be exported to a Microsoft Excel or a data delimited (e.g., .csv) file.

Note that, quite often, the valuation analyst will sign an agreement to be a Business Associate of the client for

© **HEALTH CAPITAL CONSULTANTS**
(Continued on next page)

purposes of compliance with the *Health Insurance Portability and Accountability Act of 1996* (HIPAA).[19] Nonetheless, the analyst should request the Subject Entity that the information provided not include any *protected health information* (PHI), e.g., patient name, social security number, address, date of birth. The information may include the unique patient identification or medical record number, so long as it is not tied to PHI, and related to the information provided (e.g., productivity schedules).

The specific information received from the Subject Entity should then be utilized in conjunction with the general research conducted and obtained to assist in the development of growth rates and discount rates, in preparing revenue projections and other elements of the valuation analysis pertinent to the engagement.

The paradigm shift in the healthcare reimbursement environment is changing the scope and nature of due diligence requests going forward. The due diligence requests have necessarily expanded to include both trends in the Subject Entity's historical financial performance and financial condition, as well as, more recently, the quality metrics that influence reimbursement rates. The dynamic evolution of the reimbursement environment has already resulted (at least in part) in healthcare transactions becoming increasingly complex and subject to emboldened regulatory review, requiring that the analyst seek and obtain robust general and specific research data in conducting a complete and thorough due diligence process (that will withstand scrutiny) related to the subject property interest being appraised, whether an *enterprise*, *asset*, or *service*.

---

1 For more information, see the first installment of this six part series: "The Due Diligence Imperative – For the Valuation of Healthcare Enterprises, Assets, and Services" Health Capital Consultants, Vol. 10, Issue 9, September 2017, https://www.healthcapital.com/hcc/newsletter/09_17/PDF/DILIGENCE.pdf (Accessed 10/26/17).

2 *Ibid*.

3 "Healthcare Valuation: The Financial Appraisal of Enterprises, Assets, and Services" By Robert James Cimasi, MHA, ASA, FRICS, MCBA, AVA, CM&AA, Volume 1, Hoboken, NJ: John Wiley & Sons, Inc., 2014, p. 2.

4 *Ibid*, p. 85.

5 "How the Government as a Payer Shapes the Health Care Marketplace" By Tevi D. Troy, American Health Policy Institute (AHPI), December 1, 2015, http://www.americanhealthpolicy.org/Content/documents/resources/Government_as_Payer_12012015.pdf (Accessed 8/14/2017), p. 1.

6 "National Health Expenditure Projections 2016-2025 - Tables" Center for Medicare and Medicaid Services, March 21, 2017, https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/nationalhealthaccountsprojected.html (Accessed 8/14/2017), Table 3.

7 "Medicare's Role in Determining Prices Throughout the Health Care System: Mercatus Working Paper" By Roger Feldman et al., Mercatus Center, George Mason University, October 2015, http://mercatus.org/sites/default/files/Feldman-Medicare-Role-Prices-oct.pdf (Accessed 8/14/2017), p. 3-5.

8 American Hospital Directory, https://www.ahd.com/ (Accessed 10/26/17).

9 Note that, the majority of hospitals are tax-exempt organizations. GuideStar, http://www.guidestar.org/Home.aspx (Accessed 10/26/17).

10 Cost Report Data, https://www.costreportdata.com/index.php (Accessed 10/26/17).

11 "Cost Reports" Centers for Medicare & Medicaid Services, https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Cost-Reports/ (Accessed 10/26/17).

12 "Physician Compare" Medicare.gov, https://www.medicare.gov/physiciancompare/# (Accessed 10/26/17). Note that, the procedural codes reported are *Healthcare Common Procedure Coding System* (HCPCS). See, e.g., "Medicare Provider Utilization and Payment Data: Physician and Other Supplier PUF CY2015" data.cms.gov, https://data.cms.gov/Medicare-Physician-Supplier/Medicare-Provider-Utilization-and-Payment-Data-Phy/sk9b-znav (Accessed 10/26/17).

13 Provider compensation data from MGMA is provided through its online DataDive database. MGMA DataDive, Medical Group Management Association, https://www.mgma.com/industry-data/datadive-resources (Accessed 10/26/17).

14 "Benchmarking Surveys" American Medical Group Association, https://www.amga.org/wcm/PI/surveys_pi.aspx (Accessed 10/26/17).

15 "Fee Schedules – General Information" Centers for Medicare & Medicaid Services, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/FeeScheduleGenInfo/index.html (Accessed 10/26/17).

16 "Financial & Clinical Metrics" Definitive Healthcare, https://www.definitivehc.com/financial-metrics (Accessed 10/27/17). Note that, Definitive Healthcare recently acquired Billian's HealthDATA, another type of healthcare information database. "Definitive Healthcare has acquired Billian's HealthDATA!" Definitive Healthcare, https://www.definitivehc.com/definitive-healthcare-has-acquired-billians-healthdata (Accessed 10/27/17).

17 FAIR Health, https://www.fairhealthconsumer.org/ (Accessed 10/27/17).

18 "Medicaid-to-Medicare Fee Index" The Henry J. Kaiser Family Foundation, http://www.kff.org/medicaid/state-indicator/medicaid-to-medicare-fee-index/ (Accessed 10/26/17).

19 The *Department of Health and Human Services* (HHS) defines a *business associate* as "*person or entity, other than a member of the workforce of a covered entity, who performs functions or activities on behalf of, or provides certain services to, a covered entity that involve access by the business associate to protected health information*." "Business Associate Contracts" U.S. Department of Health & Human Services, https://www.hhs.gov/hipaa/for-professionals/covered-entities/sample-business-associate-agreement-provisions/index.html (Accessed 10/27/17).

(Continued on next page)

(800)FYI - VALU

Providing Solutions in the Era of Healthcare Reform

Founded in 1993, HCC is a nationally recognized healthcare economic financial consulting firm

- HCC Home
- Firm Profile
- HCC Services
- HCC Experts
- Clients & Projects
- HCC News
- Upcoming Events
- Contact Us
- Email Us

HCC Services

- Valuation Consulting
- Commercial Reasonableness Opinions
- Commercial Payor Reimbursement Benchmarking
- Litigation Support & Expert Witness
- Financial Feasibility Analysis & Modeling
- Intermediary Services
- Certificate of Need
- ACO Value Metrics & Capital Formation
- Strategic Consulting
- Industry Research Services

Robert James Cimasi, MHA, ASA, FRICS, MCBA, CVA, CM&AA, serves as Chief Executive Officer of **Health Capital Consultants** (HCC), a nationally recognized healthcare financial and economic consulting firm headquartered in St. Louis, MO, serving clients in 49 states since 1993. Mr. Cimasi has over thirty years of experience in serving clients, with a professional focus on the financial and economic aspects of healthcare service sector entities including: valuation consulting and capital formation services; healthcare industry transactions including joint ventures, mergers, acquisitions, and divestitures; litigation support & expert testimony; and, certificate-of-need and other regulatory and policy planning consulting.

Mr. Cimasi holds a Master in Health Administration from the University of Maryland, as well as several professional designations: Accredited Senior Appraiser (ASA – American Society of Appraisers); Fellow Royal Institution of Chartered Surveyors (FRICS – Royal Institution of Chartered Surveyors); Master Certified Business Appraiser (MCBA – Institute of Business Appraisers); Certified Valuation Analyst (CVA – National Association of Certified Valuators and Analysts); and, Certified Merger & Acquisition Advisor (CM&AA – Alliance of Merger & Acquisition Advisors). He has served as an expert witness on cases in numerous courts, and has provided testimony before federal and state legislative committees. He is a nationally known speaker on healthcare industry topics, and is the author of several books, the latest of which include: "*The Adviser's Guide to Healthcare – 2nd Edition*" [2015 – AICPA]; "*Healthcare Valuation: The Financial Appraisal of Enterprises, Assets, and Services*" [2014 – John Wiley & Sons]; "*Accountable Care Organizations: Value Metrics and Capital Formation*" [2013 - Taylor & Francis, a division of CRC Press]; and, "*The U.S. Healthcare Certificate of Need Sourcebook*" [2005 - Beard Books].

Mr. Cimasi is the author of numerous additional chapters in anthologies; books, and legal treatises; published articles in peer reviewed and industry trade journals; research papers and case studies; and, is often quoted by healthcare industry press. In 2006, Mr. Cimasi was honored with the prestigious "*Shannon Pratt Award in Business Valuation*" conferred by the Institute of Business Appraisers. Mr. Cimasi serves on the Editorial Board of the Business Appraisals Practice of the Institute of Business Appraisers, of which he is a member of the College of Fellows. In 2011, he was named a Fellow of the Royal Institution of Chartered Surveyors (RICS). In 2016, Mr. Cimasi was named a "*Pioneer of the Profession*" as part of the recognition of the *National Association of Certified Valuators and Analysts* (NACVA) "*Industry Titans*" awards, which distinguishes those whom have had the greatest impact on the valuation profession.

Todd A. Zigrang, MBA, MHA, ASA, FACHE, is the President of **Health Capital Consultants** (HCC), where he focuses on the areas of valuation and financial analysis for hospitals, physician practices, and other healthcare enterprises. Mr. Zigrang has over 20 years of experience providing valuation, financial, transaction and strategic advisory services nationwide in over 1,000 transactions and joint ventures. Mr. Zigrang is also considered an expert in the field of healthcare compensation for physicians, executives and other professionals.

Mr. Zigrang is the co-author of "*The Adviser's Guide to Healthcare – 2nd Edition*" [2015 – AICPA], numerous chapters in legal treatises and anthologies, and peer-reviewed and industry articles such as: *The Accountant's Business Manual* (AICPA); *Valuing Professional Practices and Licenses* (Aspen Publishers); *Valuation Strategies; Business Appraisal Practice*; and, *NACVA QuickRead*. In addition to his contributions as an author, Mr. Zigrang has served as faculty before professional and trade associations such as the American Society of Appraisers (ASA); the National Association of Certified Valuators and Analysts (NACVA); Physician Hospitals of America (PHA); the Institute of Business Appraisers (IBA); the Healthcare Financial Management Association (HFMA); and, the CPA Leadership Institute.

Mr. Zigrang holds a Master of Science in Health Administration (MHA) and a Master of Business Administration (MBA) from the University of Missouri at Columbia. He is a Fellow of the American College of Healthcare Executives (FACHE) and holds the Accredited Senior Appraiser (ASA) designation from the American Society of Appraisers, where he has served as President of the St. Louis Chapter, and is current Chair of the ASA Healthcare Special Interest Group (HSIG).

John R. Chwarzinski, MSF, MAE, is Senior Vice President of **Health Capital Consultants** (HCC). Mr. Chwarzinski's areas of expertise include advanced statistical analysis, econometric modeling, as well as, economic and financial analysis. Mr. Chwarzinski is the co-author of peer-reviewed and industry articles published in *Business Valuation Review* and *NACVA QuickRead*, and he has spoken before the Virginia Medical Group Management Association (VMGMA) and the Midwest Accountable Care Organization Expo.

Mr. Chwarzinski holds a Master's Degree in Economics from the University of Missouri – St. Louis, as well as, a Master's Degree in Finance from the John M. Olin School of Business at Washington University in St. Louis. He is a member of the St. Louis Chapter of the American Society of Appraisers, as well as a candidate for the Accredited Senior Appraiser designation from the American Society of Appraisers.

Jessica L. Bailey-Wheaton, Esq., is Vice President and General Counsel of **Health Capital Consultants** (HCC), where she conducts project management and consulting services related to the impact of both federal and state regulations on healthcare exempt organization transactions and provides research services necessary to support certified opinions of value related to the Fair Market Value and Commercial Reasonableness of transactions related to healthcare enterprises, assets, and services. Ms. Bailey-Wheaton is a member of the Missouri and Illinois Bars and holds a J.D., with a concentration in Health Law, from Saint Louis University School of Law, where she served as Fall Managing Editor for the *Journal of Health Law & Policy*.

Daniel J. Chen, MSF, is a Senior Financial Analyst at **Health Capital Consultants** (HCC), where he develops fair market value and commercial reasonableness opinions related to healthcare enterprises, assets, and services. In addition he prepares, reviews and analyzes forecasted and pro forma financial statements to determine the most probable future net economic benefit related to healthcare enterprises, assets, and services and applies utilization demand and reimbursement trends to project professional medical revenue streams and ancillary services and technical component (ASTC) revenue streams. Mr. Chen has a M.S. in Finance from Washington University St. Louis.

© Health Capital Consultants